"I want patients to understand their options and have choices."
- Ann H. Partridge, MD, MPH
"We need to tailor therapies better for individual patients….the problem is that we overtreat the many to benefit the few."
- Lawrence J. Solin, MD
"There is risk both with treatment and with treatment deescalation, and we need to be able to quantify that trade off in a much better way for an individual patient."
- Shelley Hwang, MD, MPH
"The next few years will witness the publication of major trial results and potentially chart a new course of DCIS management."
- Lars J. Grimm, MD, MHS
At the recent 15th European Breast Cancer Conference (EBCC15), researchers shared encouraging early findings from the LORD (LOw Risk DCIS) clinical trial , a major international study exploring whether some people diagnosed with low-risk ductal carcinoma in situ (DCIS) can safely avoid immediate surgery.
Subscribe below for the latest DCIS news and updates.